KLK3 and prostate cancer: In the phase 1b/2 KEYNOTE-365 trial, patients with metastatic debulking-resistant prostate cancer treated with pablizumab plus doxorubicin and prednisone had a 34% decrease in PSA, an ORR (RECIST v1.1) of 23%, and a median rPFS and OS of 8.5 and 20.2 months, respectively (NCT02861573) [91].